QQ客服 官方微博 反馈留言

	Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers
	Lee, K. H.; Soria, J-C.; Felip, E.; Cobo, M.; Lu, S.; Syrigos, K.; Goker, E.; Georgoulias, V.; Li, W.; Guclu, S.
刊名	ANNALS OF ONCOLOGY
	2016
卷号	27
ISSN号	0923-7534
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3541645
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Lee, K. H.,Soria, J-C.,Felip, E.,et al. Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers[J]. ANNALS OF ONCOLOGY,2016,27.
APA	Lee, K. H..,Soria, J-C..,Felip, E..,Cobo, M..,Lu, S..,...&Goss, G..(2016).Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers.ANNALS OF ONCOLOGY,27.
MLA	Lee, K. H.,et al."Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers".ANNALS OF ONCOLOGY 27(2016).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。